The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Adipose tissue influences the expression and degradation of circulating biomarkers. We aimed to identify the biomarker profile and biological meaning of biomarkers associated with obesity to assess the effect of spironolactone on the circulating biomarkers and to explore whether obesity might modify the effect of spironolactone.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Card Fail

Title: Journal of cardiac failure

Publisher: Elsevier BV

ISSN (Electronic): 1532-8414

ISSN (Print): 1071-9164

Publication date (Electronic): May 2022

Volume: 28

Issue: 5

Affiliations

[1 ] Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands.

[2 ] Universite de Lorraine, Inserm, Centre d'Investigation Clinique Plurithe´matique 1433, CHRU de Nancy, F-CRIN INI-CRCT, Nancy, France.

[3 ] Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK.

[4 ] Department of Cardiology, Maastricht University Medical Center, Maastricht, the Netherlands.

[5 ] Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, East Riding of Yorkshire, UK.

[6 ] Department of Cardiology, Cortona Hospital, Arezzo, Italy.

[7 ] Department of Pathology, Maastricht University Medical Center, Maastricht, the Netherlands.

[8 ] Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charité University Medicine Berlin, Berlin Institute of Health (BIH), and German Centre for Cardiovascular research (DZHK), Berlin, Germany.

[9 ] Department of Cardiology, Maastricht University Medical Center, Maastricht, the Netherlands. Electronic address: s.heymans@maastrichtuniversity.nl.

Article

Publisher Item ID: S1071-9164(21)00501-7

DOI: 10.1016/j.cardfail.2021.12.005

PubMed ID: 34933097

SO-VID: a4abd224-67b3-429f-96b0-69595fa59b44

History

Keywords: biomarker,heart failure,spironolactone,Obesity

Data availability:

Keywords: biomarker, heart failure, spironolactone, Obesity

Comments

Comment on this article

scite_

Cited by 2

See all cited by